North America Cancer Therapeutics Market to 2031 - By Size, Share, Growth by End User and Forecast

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. North America Cancer Therapeutics Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. North America Cancer Therapeutics Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Rising Prevalence of Cancer
5.1.2 Favorable Reimbursement Scenario for Novel Therapeutics
5.1.3 Improvement in Diagnosis Rate of Cancer

5.2 Market Opportunities

5.2.1 Government Intervention across Developing Nations to Improve the Access of Life-saving Drugs
5.2.2 Rising Investments in the Development of Advanced Drug Development Platforms
5.2.3 Growing Number of Clinical trials for Anticancer Drugs

5.3 Future Trends

5.3.1 Emergence of Advanced Cell & Gene Therapies
5.3.2 Rising Adoption of Precision Medicine and Personalized Therapeutics
5.3.3 Improvement in Diagnosis Rate of Cancer

5.4 Impact of Drivers and Restraints

6. North America Cancer Therapeutics Market Regional Analysis

6.1 North America Cancer Therapeutics Market Overview

6.2 North America Cancer Therapeutics Market Revenue 2021-2031 (US$ Million)

6.3 North America Cancer Therapeutics Market Forecast Analysis

7. North America Cancer Therapeutics Market Analysis – by Therapy Type

7.1 Chemotherapy

7.1.1 Overview
7.1.2 Chemotherapy: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Targeted Therapy

7.2.1 Overview
7.2.2 Targeted Therapy: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Radiation Therapy

7.3.1 Overview
7.3.2 Radiation Therapy: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

7.4 Hormone Therapy

7.4.1 Overview
7.4.2 Hormone Therapy: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

7.5 Other Therapy Types

7.5.1 Overview
7.5.2 Other Therapy Types: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Cancer Therapeutics Market Analysis – by Indications

8.1 Blood Cancer

8.1.1 Overview
8.1.2 Blood Cancer: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8.2 Lung Cancer

8.2.1 Overview
8.2.2 Lung Cancer: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8.3 Breast Cancer

8.3.1 Overview
8.3.2 Breast Cancer: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8.4 Colorectal Cancer

8.4.1 Overview
8.4.2 Colorectal Cancer: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8.5 Prostate Cancer

8.5.1 Overview
8.5.2 Prostate Cancer: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8.6 Stomach Cancer

8.6.1 Overview
8.6.2 Stomach Cancer: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8.7 Cervical Cancer

8.7.1 Overview
8.7.2 Cervical Cancer: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8.8 Liver & Intrahepatic Bile Duct Cancer

8.8.1 Overview
8.8.2 Liver & Intrahepatic Bile Duct Cancer: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8.9 Thyroid Cancer

8.9.1 Overview
8.9.2 Thyroid Cancer: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8.10 Other Indications

8.10.1 Overview
8.10.2 Other Indications: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

9. North America Cancer Therapeutics Market Analysis – by Distribution Channel

9.1 Hospital Pharmacies

9.1.1 Overview
9.1.2 Other Indications: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

9.2 Retail Pharmacies

9.2.1 Overview
9.2.2 Other Indications: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

9.3 Online Channel

9.3.1 Overview
9.3.2 Other Indications: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

10. North America Cancer Therapeutics Market – North America Analysis

10.1 North America

10.1.1 North America Cancer Therapeutics Market Breakdown, by Key Country, 2025 and 2031 (%)
10.1.1.1 North America Cancer Therapeutics Market – Revenue and Forecast Analysis – by Country
10.1.1.1 US: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

10.1.1.1.1 US: North America Cancer Therapeutics Market Breakdown, by Therapy Type
10.1.1.1.2 US: North America Cancer Therapeutics Market Breakdown, by Indications
10.1.1.1.3 US: North America Cancer Therapeutics Market Breakdown, by Distribution Channel

10.1.1.2 Canada: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

10.1.1.2.1 Canada: North America Cancer Therapeutics Market Breakdown, by Therapy Type
10.1.1.2.2 Canada: North America Cancer Therapeutics Market Breakdown, by Indications
10.1.1.2.3 Canada: North America Cancer Therapeutics Market Breakdown, by Distribution Channel

10.1.1.3 Mexico: North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

10.1.1.3.1 Mexico: North America Cancer Therapeutics Market Breakdown, by Therapy Type
10.1.1.3.2 Mexico: North America Cancer Therapeutics Market Breakdown, by Indications
10.1.1.3.3 Mexico: North America Cancer Therapeutics Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. North America Cancer Therapeutics Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Astellas Pharma Inc

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Eli Lilly and Co

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Novartis AG

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Merck KGaA

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 AstraZeneca

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Pfizer Inc

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Hoffmann-La Roche Ltd

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Johnson & Johnson

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 AbbVie Inc

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Bristol-Myers Squibb Co

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights